Eliaz Therapeutics
Raising nowOperatingEliaz Therapeutics Inc.
Healthcare · Santa Rosa, CA · Founded 2015
Join the fight against sepsis with our life-saving medical device: XGal-3
This company has an open fundraising round.
Financials
FY2022–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round. Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher. Dashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth, so don't compare them with the other bars.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines, and each class is drawn as its own line.
Cap table
Share counts as of Apr 29, 2026| Class | Outstanding | Votes / share | Share of total | Votes | Liquidation | Last price |
|---|---|---|---|---|---|---|
| Preferred Stockpreferred | 9,900 | none | 0.11% | 0% | 1× · paid 1st | $5.56Apr 2026 |
| Class A Common Stock | 8,625,000 | 1 | 98.9% | 100.0% | — | — |
| Class B Common Stock | 84,363 | none | 0.97% | 0% | — | $5.56Jun 2026 |
| Total | 8,719,263 | 100% | 100% |
Principal holders% as the filing states it, Dec 8, 2025
- Isaac Eliaz8,000,000 Class A Common Stock81.5%of votes
- Everyone else (not named in filings)18.5%
Sold to the crowd
- Reg CF · Nov 2024$2.5M
- Reg CF · Dec 202584,543 Class B Common Stock at $5.56$470.1K· 338 investors
- Reg CF · Jun 202641,092 Class B Common Stock at $5.56$228.5K· 16 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
7 people
A Physician-researcher with 30+ years of pioneering work in Galectin-3 biology and therapeutics. Previously founded and exited ecoNugenics to a north of $30M PE firm. Holds 60+ patents and collaborates with leading research institutes such as Stanford and Mayo Clinic.
A biotech expert with 25+ years of experience, including senior roles at Genetics Institute and GlycoDesign. He co-founded Translational Medicines and served as CSO of an international glycobiology therapeutics consortium, bringing deep expertise in drug discovery and development to advance innovative therapies.
Chief of the Nephrology Division and Clinical Research Professor at Stanford School of Medicine, Dr. Chertow is among the world’s foremost experts in acute kidney injury (AKI) and chronic kidney disease (CKD), bringing unparalleled clinical and research expertise to guide the company’s medical strategy.
With an MBA and 20+ years of experience in financial management, business development, and M&A, Bryan has scaled ventures across healthcare and medtech. He specializes in securing capital, driving go-to-market strategies, and fostering strategic relationships to accelerate growth.
A former FDA Director of Medical Device division who oversaw critical medical device approvals during her 13-year tenure. Previously Senior VP at Medtronic, leading global regulatory strategy for device approvals and market access.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 1 of 2 annual reports (FY2024–FY2025)
Missing: 2024
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 15 filings on EDGAR- Form C-UJul 7, 20260001872856-26-000237EDGAR
- Form CJun 10, 20260001872856-26-000220EDGAR
- Form C-UMay 4, 20260002042609-26-000003EDGAR
- Form C-ARApr 29, 20260001872856-26-000133EDGAR
- Form C/AMar 3, 20260002042609-26-000002EDGAR
- Form CDec 8, 20250002042609-25-000007EDGAR
- Form C-UNov 28, 20250002042609-25-000005EDGAR
- Form DOct 24, 20250001062993-25-016285EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.